Products and development projects

Product

Indication

Pre-clinic

Clinical Phase

Approval

Marketed

III

Drugs on the market

Eligard^® 1)

Prostate Cancer

Veregen ^®

Genital Warts

Drugs in development

EndoTAG™-1

Pancreatic Cancer

Breast Cancer

RhuDex^®

Rh. Arthritis

²⁾

AAVLP^®

Vaccine technology

Chance of reaching the market³⁾

<10 %

<15 %

<30 %

<70 %

<90 %

¹ Sold to Astellas Pharma for € 25 million and future revenue stream
³ RhuDex^® was successfully tested in a phase IIa trial. A clinical formulation study is being prepared.
² Industrial average, estimates of MediGene AG